ArticleBreast cancer : basic and clinical research2025
Human Epidermal Growth Factor Receptor 2-Low Breast Cancer: Prevalence Rate and Scoring Concordance Among Pathologists.
Article in Breast cancer : basic and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- "HER2-Low" and the Challenge of Repurposing Legacy HER2 IHC Biomarker Assays.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) has emerged as a new category benefiting from anti-HER2 therapies. This study evaluated the prevalence of HER2-low expression and concordance of HER2 scoring among pathologists at King Hussein Cancer Center (KHCC) in Jordan. Objectives: To determine the prevalence of HER2-low breast cancer tumors and evaluate the interpathologist concordance in HER2 scoring using the 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines. Design: This is a retrospective observational study. Methods: In total, 116 breast cancer samples were randomly selected from routine practice at KHCC. Each tumor was scored for HER2 expression by 3 pathologists independently using the 2018 ASCO/CAP guidelines. Concordance among pathologists was evaluated using Fleiss' kappa and Cohen's weighted kappa statistics. Results: The original HER2 scoring revealed 7 tumors (6%) as HER2-negative (0 immunohistochemistry [IHC] score), 84 (72.4%) as HER2-low (including tumors with 1+ IHC score or 2+ IHC score with negative fluorescence in situ hybridization [FISH]), 21 (18.1%) as HER2-positive (including tumors with 3+ IHC score or 2+ IHC score with positive FISH), and 4 (3.4%) as equivocal (2+ IHC score with no FISH). Consensus scoring showed 1+ as the most frequent HER2 score. Complete agreement among all 3 pathologists occurred in 78 tumors (67.2%), while high agreement (agreement among 2 pathologists) occurred in 38 tumors (32.8%). Cohen's weighted kappa ranged from 0.691 to 0.849, indicating substantial agreement. The Fleiss kappa of overall agreement on HER2 scoring was 0.645. Conclusion: This study highlights a significant prevalence of HER2-low tumors among the randomly selected sample of Jordanian breast cancer patients and demonstrates substantial interpathologist agreement in HER2 scoring. These findings underscore the importance of standardized HER2 scoring and the potential impact of emerging therapies on a large patient population in Jordan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.